Study guide

7.2 Hypertension & Dyslipidemia Management

DHA Pharmacist Licensing Assessment PHO5481

Track your progress as you read

Finished sections get a check mark.

1 Exam Overview & Licensing Pathway

1.1 Current Exam Facts & Format 1.2 Eligibility, PQR & the Sheryan Application Process 1.3 Study Strategy & Test-Day Plan

2 Cardiovascular Pharmacology

2.1 Antihypertensives & RAAS Agents 2.2 Heart Failure & Antiarrhythmic Drugs 2.3 Lipid-Lowering & Antianginal Agents

3 Endocrine & Metabolic Pharmacology

3.1 Insulin & Oral Antidiabetic Agents 3.2 Thyroid, Bone & Calcium Agents 3.3 Corticosteroids & Other Hormonal Agents

4 Anti-Infective Pharmacology

4.1 Beta-Lactam Antibiotics 4.2 Non-Beta-Lactam Antibacterials 4.3 Antifungals, Antivirals & Antituberculars

5 CNS, Psychiatric & Pain Pharmacology

5.1 Psychiatric Pharmacology 5.2 Antiepileptics & Neurologic Agents 5.3 Analgesics: NSAIDs, Opioids & Migraine

6 Respiratory, GI & Hematology Pharmacology

6.1 Respiratory Pharmacology 6.2 Gastrointestinal Pharmacology 6.3 Anticoagulants, Antiplatelets & Hematology Agents

7 Pharmaceutical Care: Cardiometabolic Disease

7.1 Diabetes Management & Counseling 7.2 Hypertension & Dyslipidemia Management 7.3 Heart Failure & Anticoagulation Management

8 Pharmaceutical Care: Respiratory, Rheumatology & Infection

8.1 Asthma & COPD Management 8.2 Gout, Pain & Rheumatologic Care 8.3 Infection Management & Antimicrobial Stewardship

9 Counseling, Monitoring & Special Populations

9.1 Patient Counseling, Adherence & Health Literacy 9.2 Therapeutic Monitoring & Laboratory Interpretation 9.3 Pregnancy, Pediatrics, Geriatrics & Organ Impairment 9.4 Pharmacoeconomics & Formulary Decision Making

10 Pharmaceutical Calculations I

10.1 Concentration, Ratio & Percentage Strength 10.2 Weight-Based & BSA Dosing 10.3 Dilution, Concentration & Alligation

11 Pharmaceutical Calculations II

11.1 Infusion Rates & IV Flow Calculations 11.2 Dispensing Quantities & Days' Supply 11.3 Compounding Calculations, Isotonicity & Milliequivalents

12 UAE Pharmacy Law & Regulation

12.1 UAE Regulatory Framework & Licensing Authorities 12.2 Medicine Registration, Pricing & Supply Chain 12.3 Prescription Requirements & Validity

13 Controlled Drugs, Ethics & Pharmacovigilance

13.1 Controlled & Semi-Controlled Medicines in the UAE 13.2 Ethics, Confidentiality & Generic Substitution 13.3 Pharmacovigilance, Recall & Medicine Disposal

14 Pharmacokinetics I: ADME

14.1 Absorption & Bioavailability 14.2 Distribution & Protein Binding 14.3 Metabolism & Elimination

15 Pharmacokinetics II: Kinetics, Dosing & TDM

15.1 Half-Life, Clearance & Kinetic Order 15.2 Loading & Maintenance Dosing 15.3 Therapeutic Drug Monitoring

16 OTC Medicines & Self-Care

16.1 Cough, Cold & Allergic Rhinitis 16.2 GI Self-Care: Heartburn, Constipation & Diarrhoea 16.3 Pain & Fever Self-Care 16.4 Referral Red Flags, Emergency Contraception & Skin

17 Medication Safety

17.1 High-Alert Medications & Error-Prone Abbreviations 17.2 Medication Reconciliation & Duplicate Therapy 17.3 Adverse Drug Reactions & Hypersensitivity Recognition

18 Sterile & Nonsterile Compounding

18.1 Aseptic Technique & Compounding Environments 18.2 Parenteral, TPN & Cytotoxic Preparation 18.3 Nonsterile Compounding

19 Pharmaceutics, Biopharmaceutics & Toxicology

19.1 Dosage Form Design & the Biopharmaceutics Classification System 19.2 Dissolution & Excipients 19.3 Toxicology: Poisoning Recognition & Antidotes

20 Infection Control, Natural Products, Medicinal Chemistry & Pharmacogenomics

20.1 Infection Control & Immunization 20.2 Pharmacognosy & Dietary Supplements 20.3 Medicinal Chemistry Essentials 20.4 Clinical Pharmacogenomics

7.2 Hypertension & Dyslipidemia Management

Key Takeaways Explain This Topic AI

Diagnose hypertension from clinic readings ≥140/90 mmHg, then confirm with ABPM daytime average or HBPM average ≥135/85 mmHg before committing to lifelong therapy.

The ACD algorithm: ACE inhibitor/ARB first for patients under 55 who are not of black African or Caribbean origin; calcium channel blocker first for those ≥55 or of black African/Caribbean origin; step 3 adds a thiazide-like diuretic; step 4 (resistant hypertension) adds spironolactone if potassium is ≤4.5 mmol/L.

Check creatinine and potassium within about 2 weeks of starting or up-titrating an ACE inhibitor/ARB; accept a creatinine rise up to 30% and potassium up to 5.9 mmol/L before acting.

Primary-prevention statin therapy aims for at least a 40% reduction in non-HDL/LDL cholesterol (e.g., atorvastatin 20 mg); check baseline liver enzymes and only measure CK when the patient reports muscle symptoms.

Stop the statin if CK exceeds 5 times the upper limit of normal or if ALT/AST exceeds 3 times the upper limit, and always screen resistant hypertension for secondary causes and contributing drugs such as NSAIDs and steroids.

Last updated: August 2026

Measuring and Diagnosing Hypertension

Diagnosis drives years of therapy, so measurement quality matters. Counsel on correct technique: seated, back supported, arm at heart level, correct cuff size, no caffeine, smoking, or exercise within 30 minutes, and two readings taken at least one minute apart. A clinic reading of ≥140/90 mmHg suggests hypertension, but NICE-style guidance requires confirmation with ambulatory blood pressure monitoring (ABPM) or home blood pressure monitoring (HBPM) : a daytime ABPM average or HBPM average of ≥135/85 mmHg confirms the diagnosis. HBPM counseling is a pharmacist staple — measure morning and evening, seated after 5 minutes of rest, duplicate readings each occasion, for at least 4–7 days, discarding day one.

Severity staging on clinic readings: stage 1 is 140/90–159/99, stage 2 is 160/100–179/109, and severe is ≥180/110 mmHg (the latter, or any reading with acute symptoms, warrants same-day medical review rather than a routine appointment).

Treatment Thresholds and Targets

Offer antihypertensive drug treatment to all patients with stage 2 hypertension and to stage 1 patients who are under 80 with target organ damage, established cardiovascular disease, diabetes, chronic kidney disease, or a 10-year cardiovascular risk ≥10% . Above age 80 with stage 1, treat if similar comorbidities exist. The general on-treatment clinic target is <140/90 mmHg ; for patients aged 80 and over the target relaxes to <150/90 mmHg , and frailty, postural hypotension, and falls risk should always individualize the goal. Targets are tighter when confirmed by ABPM/HBPM (roughly 135/85, or 145/85 over 80).

The ACD First-Line Algorithm

NICE-style sequencing — heavily examined — is built on age and ethnicity:

  • Step Patients <55, not black African/Caribbean Patients ≥55, or black African/Caribbean any age
  • 1 A — ACE inhibitor or ARB C — calcium channel blocker
  • 2 A + C A + C
  • 3 A + C + D (thiazide-like diuretic: indapamide or chlorthalidone) A + C + D
  • 4 (resistant) A + C + D + spironolactone if K⁺ ≤4.5 mmol/L Same

The pharmacology behind the algorithm: younger patients tend toward renin-driven hypertension responsive to renin-angiotensin blockade, while older patients and those of black African/Caribbean origin more often have low-renin, salt-sensitive hypertension that responds better to calcium channel blockers and diuretics. Beta-blockers are not routine first-line unless there is a compelling indication (post-MI, heart failure, rate control in atrial fibrillation). Do not combine an ACE inhibitor with an ARB.

Monitoring and the Resistant-Hypertension Step

After starting or up-titrating an ACE inhibitor or ARB , check serum creatinine/eGFR and potassium within roughly 2 weeks . Accept up to a 30% rise in creatinine and potassium up to 5.9 mmol/L before adjusting; investigate or stop if creatinine rises more than 30% (think bilateral renal artery stenosis) or potassium reaches ≥6.0 mmol/L. An ACE-inhibitor cough (dry, persistent) justifies switching to an ARB; prior angioedema on an ACE inhibitor contraindicates the class.

Resistant hypertension is blood pressure above target despite three agents at optimal doses including a diuretic. Before labeling it, confirm adherence (the commonest cause of apparent resistance), repeat ABPM to exclude white-coat effect, and review the drug cabinet for pressor agents — NSAIDs, combined oral contraceptives, corticosteroids, decongestants, and excess licorice. Step 4 adds spironolactone 25 mg when potassium is ≤4.5 mmol/L; if potassium is higher or spironolactone is not tolerated, an alpha-blocker (doxazosin) or beta-blocker is used. Screen for secondary causes : renal artery stenosis (young patients, flash pulmonary edema, abdominal bruit), primary aldosteronism (hypokalemia, especially with resistant hypertension), obstructive sleep apnea (snoring, daytime somnolence, obesity), CKD, thyroid disease, and coarctation in the young.

Dyslipidemia: Primary vs Secondary Prevention

Secondary prevention (established ASCVD: prior MI, stroke, peripheral arterial disease, angina) means high-intensity statin therapy for essentially everyone , typically atorvastatin 80 mg, aiming for at least a 50% LDL-C reduction (ESC) with the lowest achieved LDL guiding add-on therapy. Primary prevention is risk-stratified with a validated tool — QRISK3 in NICE practice, SCORE2 in ESC practice — and statins are offered when the 10-year cardiovascular risk is ≥10% , or at lower thresholds with risk modifiers (familial hypercholesterolemia, CKD, diabetes with additional factors). The primary-prevention intensity target to quote in the exam: atorvastatin 20 mg aiming for a ≥40% reduction in non-HDL cholesterol (and LDL-C).

Statin Monitoring: Lipids, LFTs, and CK

The monitoring rules are classic exam fodder:

Baseline : full lipid profile, ALT/AST, renal and thyroid function, HbA1c; check CK only if the patient has pre-existing muscle symptoms or high-risk features.

Lipids : repeat at ~3 months to confirm the ≥40% non-HDL/LDL reduction and reinforce adherence, then annually.

LFTs : repeat at 3 months and 12 months; stop the statin if ALT/AST exceeds 3× the upper limit of normal .

CK : not routinely monitored. Measure it if the patient reports muscle pain or weakness; stop if CK exceeds 5× the upper limit of normal (with severe symptoms or renal compromise, stop regardless). If CK is 5× or less with tolerable symptoms, trial continued or reduced dosing.

For statin intolerance, trial three different statins or alternate-day dosing before labeling the patient intolerant; ezetimibe is the standard add-on or alternative. Counsel on interactions: avoid clarithromycin/erythromycin and systemic azoles with simvastatin/atorvastatin, cap simvastatin doses with amlodipine and diltiazem, and warn about large quantities of grapefruit juice with simvastatin.

Lifestyle and When to Refer

Lifestyle counseling underpins both conditions: salt restriction below ~5–6 g/day, DASH-style diet rich in fruit, vegetables, and low-fat dairy, weight loss, ≥150 minutes of weekly aerobic activity, alcohol within limits, and smoking cessation (the single largest cardiovascular risk modifier). Lipids: replace saturated with unsaturated fats, increase soluble fiber, and consider plant sterol spreads as adjuncts. Refer promptly for suspected familial hypercholesterolemia (LDL-C persistently >4.9 mmol/L with family history or tendon xanthomas), fasting triglycerides above ~10 mmol/L (pancreatitis risk), severe hypertension (≥180/110), suspected secondary hypertension, and recurrent statin-associated muscle symptoms with elevated CK.